- |||||||||| paroxetine / Generic mfg.
Journal, HEOR: Screening and Treatment of Posttraumatic Stress Disorder in Wildfire Evacuees: A Cost-Utility Analysis. (Pubmed Central) - Jun 21, 2024
Two prior studies examined the cost-effectiveness of screening followed by treatment for PTSD among individuals exposed to other disaster-type events (i.e., terrorist attack and Hurricane Sandy) and found screening followed by treatment (i.e., cognitive behavioral therapy [CBT]) to be highly cost-effective.Among wildfire evacuees, screening followed by treatment with paroxetine or trauma-focused (TF)-CBT provides additional quality-adjusted life-years (QALYs) and is cost-saving from a societal perspective. TF-CBT was the treatment option found most likely to be cost-effective.Neither treatment option was cost-effective at a willingness-to-pay threshold of $50,000 per QALY from a health care perspective.Screening programs for PTSD should be considered for wildfire evacuees, and individuals diagnosed with PTSD could be prescribed either TF-CBT or paroxetine depending on their preference and resources availability.
- |||||||||| piromelatine (Neu P11) / Neurim
Trial primary completion date: NEUP11-7: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease (clinicaltrials.gov) - Jun 21, 2024
P2/3, N=225, Active, not recruiting,
This rare case of CSVV induced by escitalopram highlights the importance of timely recognition and management of drug-induced CSVV and adds to the limited literature on selective serotonin reuptake inhibitor-associated CSVV. Trial primary completion date: May 2024 --> Jun 2025
- |||||||||| clozapine / Generic mfg.
Journal: Survey on barriers to psychiatrists' use of clozapine for young people in Scotland and suggestions for reducing these. (Pubmed Central) - Jun 20, 2024
A review of current service provision should take place, with consideration of whether the facilitators to clozapine prescription which our study has highlighted could be implemented more effectively. This may help reduce identified barriers and increase clozapine prescription to those who would benefit from it, potentially improving outcomes for young people with treatment-resistant psychosis.
- |||||||||| RE104 / Reunion Neurosci
Enrollment open: RE104 Safety and Efficacy Study in Postpartum Depression (clinicaltrials.gov) - Jun 19, 2024
P2, N=72, Recruiting,
Additionally, it is advised to administer a lower initial dose for elderly patients. Not yet recruiting --> Recruiting
- |||||||||| Resolor (prucalopride) / J&J, Takeda
Preclinical, Journal: Colitis-induced small intestinal hypomotility is dependent on enteroendocrine cell loss in mice. (Pubmed Central) - Jun 19, 2024
Not yet recruiting --> Recruiting Experimental DSS colitis induces significant small-bowel dysmotility in mice owing to enteroendocrine loss that can be reversed by genetic modulation of EEC or administering serotonin analogs, suggesting novel therapeutic approaches for patients with symptomatic colitis.
- |||||||||| memantine / Generic mfg.
Association of Acquired Immunodeficiency Syndrome with Alzheimer`s Disease-Related Dementia in HIV-Infected Individuals (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_5501;
Cox proportional hazards regression models for ADRD requiring medication such as anti-cholinesterase inhibitor or memantine were performed using baseline presence of AIDS as a predictor, after adjusting for age, sex, insurance type, and comorbidities... This study underscores the need to stratify the management of cognitive impairment in newly diagnosed HIV patients based on their baseline AIDS status and age.
- |||||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Nonpharmacologic Management of Behavioral and Psychological Symptoms of Dementia in Community-Residing Persons with Moderately-Severe Alzheimer (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_5387;
Brexpiprazole approval advanced the AD treatment armamentarium...2017), in which moderately-severe PAD-carepartner dyads (N=20) received memantine and a comprehensive, individualized, person-centered management program (CI-PCM, n=10) or usual community care (UCC, n=10), followed by a 24-week extension study... CI-PCM is an effective, readily implemented program that significantly decreased total BPSD, aggressivity, and paranoid and delusional ideation in moderately-severe PAD and significantly improved carepartner distress, depression and burden.
- |||||||||| brexpiprazole QW (OPC-34712 once weekly) / Otsuka
Efficacy of brexpiprazole on agitation in patients with dementia due to Alzheimer (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_5283;
P3
The results of this study may be used to guide decision-making. Agitation behaviors that are most bothersome to caregivers of patients with dementia due to Alzheimer
- |||||||||| Mounjaro (tirzepatide) / Eli Lilly, Belsomra (suvorexant) / Merck (MSD)
Blood-based Biomarkers to Evaluate the Effectiveness of Individualized Alzheimer (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_5028;
Improvements in amyloid and tau were observed across the preclinical to clinical spectrum of NDD. Further study in a large diverse cohort is warranted to determine the clinical utility of blood-based biomarkers in preventive neurology care.
- |||||||||| Miostat (carbachol) / Novartis
Differential Effects of Anticholinergic Medications in Patient hiPSC-Derived Neurons (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_4972;
Stem cell-derived neuronal models provide a useful strategy to complement pharmacoepidemiological studies to help distinguish molecular pathways versus confounding by indication of drugs associated with dementia risk. Preliminary results suggest that different AC medications have differential effects on AD-associated cellular outcomes that are consistent across hiPSC-Ns derived from individuals with various genetic backgrounds, indicating a molecular effect of the drug.
- |||||||||| quetiapine / Generic mfg.
Neuroprotective potential of quetiapine against streptozotocin-induced sporadic Alzheimer's disease. (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_4951;
Preliminary results suggest that different AC medications have differential effects on AD-associated cellular outcomes that are consistent across hiPSC-Ns derived from individuals with various genetic backgrounds, indicating a molecular effect of the drug. The conclusive outcomes of the present study, clearly indicate neuroprotective potential of quetiapine in neurodegenerative pathogenesis associated with cognitive dysfunction.
- |||||||||| Nuplazid (pimavanserin) / Acadia Pharma
Psychosis in Alzheimer's Disease (Hall A (Pennsylvania Convention Center)) - Jun 19, 2024 - Abstract #AAIC2024AAIC_4606;
Phase-3 study data readout is anticipated in Q1/Q2 2025. Emerging potential therapies include the 5HT2A inverse agonist pimavanserin, which is already licensed in the US for the treatment of Parkinson
- |||||||||| memantine / Generic mfg.
Development of Diverse Carbon Dots to Inhibit Protein Aggregation in Alzheimer (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_3681;
Overall, the data suggests CDs have a unique ability to inhibit the aggregation of both AD hallmarks. This data encourages investing further research into CDs for the future treatment of AD.
- |||||||||| memantine / Generic mfg.
Management of Cognitive and Autonomic Symptoms in LBD (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_3153;
The US Based Diamond Lewy Cognitive Symptoms management document presents the unique cognitive profile of LBD with general principles for addressing these features along with detailed guidance in the use of cholinesterase inhibitors and Memantine. The US Based Diamond Lewy Autonomic Symptoms management document addresses the management of common autonomic symptoms including urinary dysfunction, male sexual dysfunction, excessive sweating, constipation, sialorrhea , gastroparesis and orthostatic hypotension in LBD.
- |||||||||| memantine / Generic mfg.
Effects of Memantine on okadaic acid induced neurotoxicity at the systemic and molecular level in rats (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_2714;
The US Based Diamond Lewy Autonomic Symptoms management document addresses the management of common autonomic symptoms including urinary dysfunction, male sexual dysfunction, excessive sweating, constipation, sialorrhea , gastroparesis and orthostatic hypotension in LBD. Thus, our results support the presumption that ?7 nACh receptors may play an important role in the cognitive enhancer effects of memantine and emphasize the role of cholinergic-glutamatergic interactions in memory.
- |||||||||| agomelatine / Generic mfg.
Evaluating the repurposing potential of the anti-depressant Agomelatine for Alzheimer's Disease (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_2659;
This finding paired with the decrease of DDIT3 gene expression suggests that Agomelatine has a neuroprotective mechanism that is independent of amyloid burden. Future studies will analyze neuronal loss via NeuN staining to determine if AGO prevents neuronal loss, thus supporting its ability to mitigate cognitive deficits in the TgF344-AD rat model.
- |||||||||| Auvelity (bupropion/dextromethorphan) / Axsome Therap
Clinical Profile of AXS-05 in Treating Alzheimer (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_2508;
P2/3, P3
Future studies will analyze neuronal loss via NeuN staining to determine if AGO prevents neuronal loss, thus supporting its ability to mitigate cognitive deficits in the TgF344-AD rat model. AXS-05 demonstrated a substantial , rapid reduction in ADA vs controls after 5 weeks of treatment , increased time-to-relapse vs placebo , and was well - tolerated, supporting its development as a promi sing treatment option for ADA.
- |||||||||| Auvelity (bupropion/dextromethorphan) / Axsome Therap
Efficacy and Safety Of AXS-05 in Agitation Associated with Alzheimer (201 ABC (Pennsylvania Convention Center)) - Jun 19, 2024 - Abstract #AAIC2024AAIC_2435;
P3
AXS-05 demonstrated a substantial , rapid reduction in ADA vs controls after 5 weeks of treatment , increased time-to-relapse vs placebo , and was well - tolerated, supporting its development as a promi sing treatment option for ADA. AXS-05 substantially reduced the risk of agitation symptom relapse in participants with AD and was generally well-tolerated in those who achieved sustained clinical response in the OL period.
- |||||||||| escitalopram / Generic mfg.
Escitalopram for Agitation in Alzheimer (201 ABC (Pennsylvania Convention Center)) - Jun 19, 2024 - Abstract #AAIC2024AAIC_2433;
Citalopram was effective in treating agitation in AD but was associated with cognitive and cardiac risks linked to its R- but not S-enantiomer. As escitalopram is a most commonly used treatment for disruptive behavior in dementia, the outcomes whether positive or negative will have major clinical impact.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Therapeutic potential of beta-carotene on intracisternal injection of glucose oxidase-induced senile dementia in diabetic rats (Virtual) - Jun 19, 2024 - Abstract #AAIC2024AAIC_2265;
Besides, only a few medications were approved for the symptomatic relief of SD i.e., donepezil, galantamine, rivastigmine, and memantine. The present results revealed that BC possesses the ameliorative potential against GOD-induced neurotoxicity and SD due to its anti-oxidative, anti-cholinesterase, reduction of IR, prevention of microglial activation, and enhancement of the glucose update actions.
- |||||||||| memantine / Generic mfg.
Potential effects of sweet almond oil in the treatment of Alzheimer (Virtual) - Jun 19, 2024 - Abstract #AAIC2024AAIC_2109;
12 compounds were found to have a higher binding affinity than Memantine, a drug that was reported to upregulate BDNF/TrkB expression in the brain... The results of this study revealed that some compounds of sweet almond oil have potential therapeutic activity against BDNF/TrkB expression with low systematic toxicity.
- |||||||||| memantine / Generic mfg., quetiapine / Generic mfg.
Community Psychiatry Clinic's Impact on Dementia Care: Insight from Rythm Community Mental Healthcare Program (Virtual) - Jun 19, 2024 - Abstract #AAIC2024AAIC_1852;
Medications such as Donepezil, Memantine, Quetiapine, and Melatonin are employed based on symptom profiles, with Quetiapine being a commonly used antipsychotic. Community psychiatry clinics significantly impact dementia care by offering targeted case identification, caregiver education, and comprehensive services, ultimately contributing to improved community-level dementia care and awareness.
- |||||||||| risperidone / Generic mfg., escitalopram / Generic mfg.
Effect of combination treatment with escitalopram and risperidone in punding behaviour among patients with dementia- a retrospective study (Virtual) - Jun 19, 2024 - Abstract #AAIC2024AAIC_1593;
By leveraging personalized prediction models based on individual clinical features, our research aims to equip clinicians with tools for more informed and patient-specific decisions concerning risperidone treatment. The study adds valuable insights into the management of punding behavior and its associated distress providing a basis for further research on the neurobiological underpinnings of this distinctive symptom in dementia.
- |||||||||| trazodone ER / Generic mfg.
Evolution of BPSD and psychotropic drug therapy in patients with dementia (Virtual) - Jun 19, 2024 - Abstract #AAIC2024AAIC_1584;
In older patients with dementia, BPSD gradually increased, together with functional and cognitive decline over 12 months. Managing agitation led to an increased prescription of trazodone, while antidepressant medications were used in follow-ups for depressive symptoms; more importantly, prescription of antipsychotics did not increase, aligning with recommendations regarding their safety profile.
- |||||||||| alhydrogel injectable (AD04) / ADvantage Therap, ondansetron ultra-low dose (AD04) / Adial
AD04 (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_1436;
Based on these preclinical results we conclude that AD04 administration induces microglia to phagocytose brain debris, such as apoptotic neurons, synapses and degraded myelin in the aged brain, and in the AD brain also Abeta, extracellular tau tangles and oxidized lipids. By changing the microglial phenotype, AD04, indirectly reduces the neuroinflammation induced by Abeta, tau and neuronal debris, leading to an anti-inflammatory milieu in the brain which protects and rescues the hippocampus from neurodegeneration.
|
